Browse News
Filter News
Found 763,228 articles
-
Data from the Phase IIb ENLIVEN trial showed 89bio’s pegozafermin met its primary histology endpoint in NASH patients, giving the company an edge in the competitive space.
-
Flare Therapeutics closed Wednesday an oversubscribed Series B funding round, counting $123 million in earnings, which it will use to advance its lead precision oncology asset FX-909 in urothelial cancer.
-
Yescarta is the first treatment in nearly 30 years to improve overall survival in relapsed/refractory large B-cell lymphoma R/R LBCL, according to Gilead's Kite Pharma.
-
Mayank Mamtani, managing director and group head of healthcare research at B. Riley Securities, told BioSpace he believes Altimmune's pemvidutide still shows promise despite safety concerns.
-
Sponsored: Inspirational Space Sparks Scientific Innovation at the First Life Sciences Building i...
3/22/2023
Real estate development firm Sterling Bay launches life sciences division starting with Lincoln Yards, a 320,000 square foot site on the Chicago River. -
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3/22/2023
Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of March 20, 2023, under the Standard BioTools Inc.
-
Aziyo Biologics and Sientra Announce SimpliDerm® Partnership to Improve Women’s Access to Biologics for Soft Tissue Reconstruction
3/22/2023
Aziyo Biologics, Inc. and Sientra, Inc. today announced they have entered into an agreement to expand the distribution of Aziyo’s SimpliDerm product line.
-
Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights
3/22/2023
Inozyme Pharma, Inc today reported financial results for the full year ended December 31, 2022, and provided recent business highlights.
-
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
3/22/2023
Tenax Therapeutics, Inc. announced today that the Company has been issued a patent by the United States Patent and Trademark Office (USPTO) with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension associated with HFpEF.
-
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
3/22/2023
AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
-
Dario Announces Strategic Partnership with Amwell to Expand Access to its Cardiometabolic Digital Therapeutic Solution
3/22/2023
DarioHealth Corp. announced today a strategic partnership with Amwell to deliver its cardiometabolic solution to Amwell customers.
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 22, 2023
3/22/2023
Schrödinger, Inc. today reported that on March 19, 2023, the company granted non-statutory stock options to purchase an aggregate of 32,700 shares of the company’s common stock to 10 newly hired employees, including two newly hired employees based outside of the United States.
-
Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease
3/22/2023
Maze Therapeutics today announced new data from an exploratory muscle biopsy cohort of its Phase 1 clinical trial of MZE001 in healthy volunteers to evaluate the effects of MZE001 on glycogen synthesis.
-
Athersys Announces Successful Type B Meeting with the FDA
3/22/2023
Athersys, Inc. announced planned amendments to its MASTERS-2 clinical trial protocol following a Type B meeting with the U.S. Food & Drug Administration (FDA).
-
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
3/22/2023
FSD Pharma Inc. today announced that its Australian entity, FSD Pharma Australia Pty Ltd. received the certificate of approval from The Alfred Ethics Committee in Australia to proceed with a Phase 1 study.
-
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
3/22/2023
Vistagen today announced positive data from its Phase 3 open-label study designed to evaluate the safety and tolerability of multiple, as-needed intranasal administrations of fasedienol (PH94B) over time in adults with social anxiety disorder (SAD).
-
Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease
3/22/2023
Cognito Therapeutics announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors.
-
Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care
3/22/2023
Massive Bio, Inc. and NeoGenomics, Inc. today announced a collaboration with the goal of accelerating the development of new cancer therapies and ultimately improving the lives of millions of cancer patients around the world.
-
Jacobio Pharma Announces 2022 Annual Results
3/22/2023
Jacobio Pharma (1167.HK) announced its 2022 annual results. R&D investment was RMB530 million , showing an increase of 26% compared with 2021.
-
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
3/22/2023
Astria Therapeutics today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.